Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection

Basit Öğe Kaydı
dc.authorid0000-0002-3386-1734
dc.contributor.authorMaen, Abdelrahim
dc.contributor.authorGök Yavuz, Betül
dc.contributor.authorMohamed, Yehia I.
dc.contributor.authorEsmail, Abdullah
dc.contributor.authorLu, Jianming
dc.contributor.authorMohamed, Amr
dc.contributor.authorAzmi, Asfar S.
dc.contributor.authorKaseb, Mohamed
dc.contributor.authorKasseb, Osama
dc.contributor.authorLi, Dan
dc.contributor.authorGocio, Michelle
dc.contributor.authorKoçak, Mehmet
dc.contributor.authorSelim, Abdelhafez
dc.contributor.authorMa, Qing
dc.contributor.authorKaseb, Ahmed O.
dc.date.accessioned2024-03-06T12:36:54Z
dc.date.available2024-03-06T12:36:54Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Biyoistatistik ve Tıp Bilişimi Ana Bilim Dalı
dc.description.abstractThymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants in-vitro, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients.
dc.identifier.citationMaen, A., Gök Yavuz, B., Mohamed, Y. I., Esmail, A., Lu, J., Mohamed, A. ... Kaseb, A. O. (2024). Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection. Frontiers in Pharmacology, 15. https://dx.doi.org/10.3389/fphar.2024.1291212
dc.identifier.doi10.3389/fphar.2024.1291212
dc.identifier.issn1663-9812
dc.identifier.pmid38379905
dc.identifier.scopus2-s2.0-85185316688
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://dx.doi.org/10.3389/fphar.2024.1291212
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12340
dc.identifier.volume15
dc.identifier.wos001164632500001en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKoçak, Mehmet
dc.language.isoen
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers in Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectCOVID-19
dc.subjectThymoquinone TQ
dc.subjectCoronavirus
dc.subjectCOVID-19 and Anti-Viral Agents
dc.subjectTQ Formula
dc.subjectFatty Acids
dc.titleIndividual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Kocak-Mehmet-2024.pdf
Boyut:
2.34 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu